Sakurai Kenichi, Enomoto Katsuhisa, Kitajima Akira, Tani Mayumi, Amano Sadao
Division of Breast and Endocrine Surgery, Dept. of Surgery, Nihon University School of Medicine.
Gan To Kagaku Ryoho. 2007 Nov;34(12):1911-3.
We compared trastuzumab alone therapy (A-group) (n=6) to trastuzumab plus taxane therapy (B-group) (n=12) in patients of advanced and metastatic breast cancers. The response rate of A-group was 33.3%. Six months after, A-group was switched to trastuzumab plus taxane therapy. The response rate of A-group after addition of taxane was improved to 83.3%. The mean duration of response was 6.8 months in A-group after addition of taxane. The response rate of B-group was 83.3%. The mean duration of response was 7.5 months in B-group. The combination therapy of trastuzumab and taxane therapy showed a high response rate. We think that it is possible to start trastuzumab alone therapy because A-group after addition of taxane showed a high response rate. There were no significant differences of immunosuppressive acidic protein (IAP) from the course of chemotherapy in all cases.
我们将晚期和转移性乳腺癌患者的单纯曲妥珠单抗治疗组（A组，n = 6）与曲妥珠单抗加紫杉烷治疗组（B组，n = 12）进行了比较。A组的缓解率为33.3%。六个月后，A组改为曲妥珠单抗加紫杉烷治疗。添加紫杉烷后A组的缓解率提高到了83.3%。添加紫杉烷后A组的平均缓解持续时间为6.8个月。B组的缓解率为83.3%。B组的平均缓解持续时间为7.5个月。曲妥珠单抗与紫杉烷联合治疗显示出较高的缓解率。我们认为可以开始单纯曲妥珠单抗治疗，因为添加紫杉烷后的A组显示出较高的缓解率。所有病例化疗过程中免疫抑制酸性蛋白（IAP）均无显著差异。
Zotero 插件